Forest memantine neuropathic pain trial fails
Executive Summary
Forest is reviewing plans to develop diabetes agent memantine for neuropathic pain after Phase III clinical trial "failed to demonstrate a statistically significant difference versus placebo," Forest says. An earlier pivotal trial met endpoints for nocturnal pain in patients with diabetic neuropathy. Memantine is one product Forest is counting on to support long-term growth following loss of exclusivity for Celexa (1"The Pink Sheet" April 28, p. 33)...
You may also be interested in...
Forest Counting On Memantine, Benicar, To Bolster Growth Post-Celexa
Forest expects its Alzheimer's drug memantine to be approved for moderate to severe disease in the spring of 2004, Chief Operating Officer Kenneth Goodman said during a fiscal 2003 fourth quarter earnings call April 22
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.